FMC continues to face crop protection destocking pressure with generic competition eroding diamides franchise margins. Channel inventory normalization has taken longer than guided. Biologicals segment growth helpful but not enough to offset legacy headwinds. Patent expirations on key products tighten the medium-term outlook.
Thesis reviewed May 29, 2026
FMC Corporation is headquartered in United States, which is currently showing elevated risk signals.
πΊπΈUnited States82EXITView United States risk detail βπΎAgriculture19REDUCE| Ticker | Company | Score | Gap | Signal Ξ | Action |
|---|---|---|---|---|---|
| FMC | FMC Corporation | 25 | -6% | β89% | AVOID |
| BG | Bunge Global SA | 25 | +12% | β89% | EARLY |
| CAG | Conagra Brands Inc. | 25 | -10% | β89% | AVOID |
| ANDE | The Andersons, Inc. | 25 | +7% | β89% | NEUTRAL |
| ADM | Archer-Daniels-Midland Company | 25 | +4% | β89% | NEUTRAL |
| DE | Deere & Company | 25 | +6% | β89% | NEUTRAL |
| IPI | Intrepid Potash, Inc. | 25 | +11% | β89% | EARLY |
Investors who hold FMC may also have indirect exposure through these country funds.
FMC lowers FY26 guidance citing pricing pressure on diamides
Generic chlorantraniliprole supply expands into Brazil season
Estimates Β· Yahoo Finance Β· Not audited figures
| Politician | Party | Type | Amount | Trade Date | Return |
|---|---|---|---|---|---|
| Dan NewhouseWA | Buy | $1kβ$15k | Jul 10, 26 |